The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD candidates with blockbuster potential. According to Reuters, MSD – known as Merck & Co in ...
MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...
China’s microelectromechanical systems (MEMS) sensor industry is surging, but technical gaps, fragmented production and coordination challenges hinder its full potential. As global demand accelerates, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results